Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.35 |
| ▸ | DRD5 | P21918 | 1/20 | 0.35 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | HTR1B | P28222 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | STAT3 | P40763 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.31 |
| ▸ | SCN2B | O60939 | 1/20 | 0.31 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL4902056 | 0.86 | KDM4E (0.49) | CYP1A2CYP2D6CYP2C9CYP2C19KDM4E | |
| SCHEMBL4909282 | 0.80 | KAT2B (0.34) | HTR7DRD2DRD1DRD4DRD5 | |
| SCHEMBL4908710 | 0.78 | HTR7 (0.35) | HTR7DRD2DRD1DRD4DRD5 | |
| SCHEMBL6892797 | 0.77 | DRD2 (0.58) | HTR7DRD2DRD1DRD4DRD5 | |
| SCHEMBL7755878 | 0.74 | LTA4H (0.56) | CHRNB2CHRNA4CYP1A2CYP2D6CYP2C9 | |
| SCHEMBL6650105 | 0.73 | NR4A2 (0.42) | DRD2DRD1DRD4DRD5CHRNB2 | |
| SCHEMBL6651356 | 0.73 | DRD2 (0.44) | HTR7DRD2DRD1DRD4DRD5 | |
| SCHEMBL20706621 | 0.72 | ADRA1D (0.43) | KAT2BKDM4E | |
| SCHEMBL6651166 | 0.68 | KDM4E (0.38) | HTR7DRD2DRD1DRD4DRD5 | |
| Citric Acid SCHEMBL8657218 | 0.66 | KDM4E (0.70) | DRD2DRD1DRD4DRD5CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2008-08-21 | — | — | US | claimed |
| EP-1820502-A1 | Active substance combination comprising azolylcarbinol compounds | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-08-22 | — | — | EP | claimed |
| EP-1786419-A1 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS (IN PARTICULAR CIZOLIRTIN CITRATE) FOR THE TREATMENT OF OPIOID ADDICTION | Laboratorios del Dr. Esteve S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| EP-1786420-A1 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS FOR THE TREATMENT OF CENTRAL NEUROPATHIC PAIN | Laboratorios del Dr. Esteve S.A. (ES) | 2007-05-23 | — | — | EP | claimed |
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | LABORATORIOS DEL DR. ESTEVE S.A. (ES) | 2007-04-19 | — | — | US | claimed |
| US-20070082893-A1 | Active substance combination | LABORATORIOS DEL DR. ESTEVE S.A (ES) | 2007-04-12 | — | — | US | claimed |
| EP-1755678-A2 | ACTIVE SUBSTANCE COMBINATION OF A CARBINOL COMPOUND AND AN OPIOID | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-02-28 | — | — | EP | claimed |
| WO-2005097192-A9 | ACTIVE SUBSTANCE COMBINATION OF A CARBINOL COMPOUND AND AN OPIOID | ESTEVE LABOR DR (ES) | 2007-01-18 | — | — | WO | claimed |
| EP-1695704-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-30 | — | — | EP | claimed |
| WO-2006087147-A2 | DERIVATIVES OF ARYL (OR HETEROARYL) AZOLYLCARBINOLS FOR THE TREATMENT OF FIBROMYALGIA | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2006-08-24 | — | — | WO | claimed |
| US-20040162324-A1 | Thienylazolylalkoxyethanamines, their preparation and their application as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. | 2004-08-19 | — | — | US | claimed |
| US-20040142929-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2004-07-22 | — | — | US | claimed |
| EP-1103243-B1 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES FOR THE TREATMENT OF TROUBLES MEDIATED BY AN EXCESS OF SUBSTANCE P | ESTEVE LABOR DR (ES) | 2004-01-07 | — | — | EP | claimed |
| EP-1086682-B1 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF NEUROGENIC INFLAMMATION | ESTEVE LABOR DR (ES) | 2003-04-16 | — | — | EP | claimed |
| US-6518295-B1 | Such as anxiety, depression, schizophrenia, manic depressive psychosis, sexual dysfunction, drug addiction, cognitive disorders, and locomotive disorders | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2003-02-11 | — | — | US | claimed |
| US-20020188017-A1 | Thienylazolylalkoxyethanamines, their preparation and their application as medicaments | LABORATORIOS DEL DR. ESTEVE, S.A. | 2002-12-12 | — | — | US | claimed |
| US-6410582-B1 | ANALGESICS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2002-06-25 | — | — | US | claimed |
| EP-1103243-A2 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF TROUBLES MEDIATED BY AN EXCESS OF SUBSTANCE P | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-05-30 | — | — | EP | claimed |
| EP-1086682-A2 | UTILIZATION OF ARYL(OR HETEROARYL)AZOLYLCARBINOL DERIVATIVES IN THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF NEUROGENIC INFLAMMATION | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-03-28 | — | — | EP | claimed |
| EP-1072266-A1 | THIENYLAZOLYLALCOXYETHANAMINES, THEIR PREPARATION AND THEIR APPLICATION AS MEDICAMENTS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2001-01-31 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142929-A1 | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence | AADAC, AHR, ABAT | HTR7 455/4885DRD2 1336/4885DRD1 1457/4885 |
| US-20020188017-A1 | Thienylazolylalkoxyethanamines, their preparation and their application as medicaments | HNMT, HRH4, PNMT | HTR7 26/4885DRD2 45/4885DRD1 71/4885 |
| US-20040162324-A1 | Thienylazolylalkoxyethanamines, their preparation and their application as medicaments | HNMT, HRH4, PNMT | HTR7 26/4885DRD2 45/4885DRD1 71/4885 |
| US-20070088024-A1 | Active substance combination comprising a carbinol combined to at least an NSAID | PTGS1, PTGS2, PTGES2 | HTR7 839/4885DRD2 365/4885DRD1 647/4885 |
| US-20080200693-A1 | Derivatives of Aryl (or Heteroaryl) Azolylcarbinols (in Particular Cizolirtin Citrate) for the Treatment of Opioid Addiction | CNR2, CNR1, HCRTR2 | HTR7 920/4885DRD2 217/4885DRD1 426/4885 |
| US-20070082893-A1 | Active substance combination | OPRM1, OPRK1, OPRL1 | HTR7 499/4885DRD2 27/4885DRD1 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.